Tiragolumab/Atezolizumab Shows No Benefit in NSCLC ...Middle East

Medscape - News
Tiragolumab/Atezolizumab Shows No Benefit in NSCLC
A phase 3 study of tiragolumab plus atezolizumab in patients with PD-L1–high NSCLC shows numerical survival improvements but fails to meet statistical endpoints. Medscape Medical News

Hence then, the article about tiragolumab atezolizumab shows no benefit in nsclc was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Tiragolumab/Atezolizumab Shows No Benefit in NSCLC )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News